Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02648477
Title Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Letrozole + Pembrolizumab

Exemestane + Pembrolizumab

Anastrozole + Pembrolizumab

Doxorubicin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.